Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands
Objectives Current guidelines recommend tapering biological disease-modifying antirheumatoid drugs (bDMARDs) in rheumatoid arthritis (RA) if the disease is under control. However, guidelines on tapering are lacking. Assessing cost-effectiveness of different tapering strategies might provide broader input for creating guidelines on how to taper bDMARDs in patients with RA. The aim of this study is to evaluate the long-term cost-effectiveness from a societal perspective of bDMARD tapering strategies in Dutch patients with RA, namely 50% dose reduction (tapering), discontinuation and a 50% dose r... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | TEXT |
Erscheinungsdatum: | 2023 |
Verlag/Hrsg.: |
BMJ Publishing Group Ltd
|
Schlagwörter: | Rheumatoid arthritis |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26806124 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://ard.bmj.com/cgi/content/short/82/10/1296 |